Clinical Trial Update: The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis [NA]

View source ↗

Summary

A clinical trial update evaluating the efficacy and safety of chiglitazar for metabolic dysfunction-associated fatty liver disease (MAFLD) with compensated cirr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Compensated Cirrhosis
• Metabolic Dysfunction-associated Fatty Liver Disease

Drugs mentioned

• Chiglitazar (Chiglitazar)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Metabolic Dysfunction Associated Fatty Liver Disease, Compensated Liver Cirrhosis | NA | Status: NOT_YET_RECRUITING